Title
New viral and non-viral platforms for T-cell engineering
Conference Dates
January 27-31, 2019
Abstract
FDA approval of the first Chimeric Antigen Receptor T cell (CAR-T) therapy offers cancer patients more promise than ever for curative effects. However, many technical challenges in T cell gene delivery still remain in order for this therapy to become a standard of care practice. In this webinar, we will highlight the different viral and non-viral delivery approaches used in T cell engineering for cell and gene therapy applications including: New solution for small-to-large scale serum-free, suspension lentiviral production – LV-MAX™ Lentiviral Production System o Platform development process using Design of Experiment (DOE) methodologies o High-throughput to large scale bioreactor protocols o Cost benefits of this system over current methods Novel gene editing tools for primary T cells o New potent gene editing tools to increase knock-in and knock-out efficiency o Addressing non-viral delivery barriers through protocol optimization Learning Objectives: Current industry trends and challenges of cell and gene therapy manufacturing Benefits of innovative new upstream technologies for virus generation in suspension
Recommended Citation
Chad MacArthur, "New viral and non-viral platforms for T-cell engineering" in "Advancing Manufacture of Cell and Gene Therapies VI", Dolores Baksh, GE Healthcare, USA Rod Rietze, Novartis, USA Ivan Wall, Aston University, United Kingdom Eds, ECI Symposium Series, (2019). https://dc.engconfintl.org/cell_gene_therapies_vi/29